Phase
Condition
Carcinoid Syndrome And Carcinoid Tumours
Neuroendocrine Carcinoma
Abdominal Cancer
Treatment
ATRX/DAXX immunohistochemistry
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥18 years
Cyto/histologic diagnosis of pNETs
Signed informed consent
Exclusion
Exclusion Criteria:
Functional pNETs
Multiple pancreatic nodules
Diagnosis of MEN-1 or Von-Hippel Lindau
Mixed types (e.g., mixed neuroendocrine-acinar/adenocarcinoma) or neuroendocrinecarcinomas
Predominantly cystic lesions (more than 50% of the volume).
Metastatic tumors at the time of diagnosis
Known bleeding disorder that cannot be sufficiently corrected with co-fact or freshfrozen plasma
Use of anticoagulants that cannot be discontinued
INR >1.5 or platelet count <50.000
Pregnancy or breastfeeding
Failure to sign the patient's or closest relative's informed consent
Study Design
Connect with a study center
University Hospital of Verona
Verona,
ItalySite Not Available
University Hospital of Verona
Verona 3164527,
ItalySite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.